Clinical trials: Extensive Stage Small Cell Lung Carcinoma
- Condition Extensive Stage Small Cell Lung Carcinoma
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Extensive Stage Small Cell Lung Cancer
A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC
This is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10+ Chemotherapy vs placebo+Chemotherapy in Previously Untreated Patients with Extensive Stage Small Cell…
- Trial name
- NCT04063163
- Testing
- HLX10, carboplatin and etoposide
- Where
- 5 sites in Georgia, Poland and 3 more
- Volunteers
- 585 people
- Sponsor
- Shanghai Henlius Biotech
Small-cell Lung Cancer
SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy
This is a multi-center, open-label, phase II study of intravenous (IV) SHR-1210 at 200mg,q2w in combination with Apatinib at one dose (375mg).
- Trial name
- PASSION (NCT03417895)
- Testing
- SHR-1210, Apatinib
- Where
- 2 sites in China
- Volunteers
- 59 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Extensive-stage Small Cell Lung Cancer
Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.
- Trial name
- LUMINANCE (NCT04774380)
- Testing
- Durvalumab, Cisplatin, Carboplatin
- Where
- 35 sites in Bulgaria, Canada and 4 more
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Extensive-stage Small-cell Lung Cancer
Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients
A Randomized, double-blind, placebo-controlled, multi-center Phase 3 study evaluating efficacy, safety and pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin combined with…
- Trial name
- NCT04902885
- Testing
- Trilaciclib, carboplatin, etoposide，or Topotecan
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Small-Cell Lung Cancer
Study of AZD2811 + Durvalumab in ES-SCLC
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with…
- Trial name
- TAZMAN (NCT04745689)
- Testing
- Durvalumab, AZD2811, Carboplatin
- Where
- 12 sites in United States, Poland and 2 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28), a Cyclin Dependent Kinase (CDK) 4/6 inhibitor, in preserving the bone marrow and the immune system, in order to decrease chemotherapy-induced…
- Trial name
- NCT02514447
- Testing
- Trilaciclib, Topotecan
- Where
- 50 sites in United States, Belgium and 6 more
- Volunteers
- 123 people
- Sponsor
- G1 Therapeutics, Inc.
Small Cell Lung Carcinoma
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with…
- Trial name
- NCT05224141
- Testing
- Pembrolizumab/Vibostolimab Co-Formulation, Etoposide, Cisplatin
- Where
- 140 sites in United States, Argentina and 23 more
- Volunteers
- 460 people
- Sponsor
- Merck Sharp & Dohme LLC
Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
The purpose of this study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).
- Trial name
- NCT03026166
- Testing
- Ipilimumab, Nivolumab, Rovalpituzumab tesirine
- Where
- 35 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- AbbVie
Solid Tumor, Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)
This study using pembrolizumab (MK-3475) will be done in 5 parts. In Part A, successive participant cohorts with advanced solid tumors will receive pembrolizumab to assess the safety and tolerability of monotherapy.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT01840579
- Testing
- Pembrolizumab 2 mg/kg, Pembrolizumab 10 mg/kg, Pembrolizumab 200 mg
- Volunteers
- 57 people
- Sponsor
- Merck Sharp & Dohme LLC
Extensive-Stage Small-Cell Lung Cancer
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for patients with…
- Trial name
- NCT01987232
- Testing
- Carfilzomib, Carboplatin, Etoposide
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 32 people
- Sponsor
- Amgen
Stage IV Small Cell Lung Cancer
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 (tarextumab) in combination with etoposide (EP) for 6 cycles followed a Phase 2, multi center, randomized…
- Trial name
- PINNACLE (NCT01859741)
- Testing
- OMP-59R5, Etoposide, Cisplatin or Carboplatin
- Where
- 35 sites in United States
- Volunteers
- 172 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Small Cell Lung Carcinoma Extensive Disease
Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)
This will be an open-label, single-arm, multicenter, Phase IIIb study to determine the safety of durvalumab + etoposide and cisplatin or carboplatin as first-line treatment in patients with extensive stage small-cell lung cancer.
- Trial name
- NCT04449861
- Testing
- Durvalumab plus chemotherapy
- Where
- 30 sites in China
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer
A Study for Participants With Small-Cell Lung Cancer
Part A: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer. Part B: This study evaluates an experimental treatment in participants with extensive-disease in small-cell…
- Trial name
- NCT01025284
- Testing
- LY2523355, Granulocyte colony-stimulating factor (G-CSF)
- Where
- 11 sites in United States, Romania and 1 more
- Volunteers
- 64 people
- Sponsor
- Eli Lilly and Company
Extensive-stage Small Cell Lung Cancer
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared…
- Trial name
- NCT04702880
- Testing
- BMS-986012, Carboplatin, Etoposide
- Where
- 39 sites in United States, Australia and 9 more
- Volunteers
- 135 people
- Sponsor
- Bristol-Myers Squibb
Small Cell Lung Carcinoma Extensive Disease
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab…
- Trial name
- CASPIAN (NCT03043872)
- Testing
- Durvalumab, Tremelimumab, Carboplatin
- Where
- 207 sites in United States, Argentina and 21 more
- Volunteers
- 987 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer
Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer
The purpose of this study is to determine if cisplatin and pemetrexed are effective in the treatment of patients with Small Cell Lung Cancer, extended disease.
- Trial name
- NCT00475657
- Testing
- pemetrexed, cisplatin
- Where
- 6 sites in Spain
- Volunteers
- 5 people
- Sponsor
- Eli Lilly and Company
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
Study design This is a Phase II, open-label, multi-drug, multi-center, multi-arm, signal-searching study in patients with extensive-stage small-cell lung cancer (SCLC) who have refractory or resistant disease from prior…
- Trial name
- NCT02937818
- Testing
- Durvalumab and Tremelimumab, AZD1775 and carboplatin (CBPT), AZD6738 and olaparib
- Where
- 12 sites in Germany, Hungary and 3 more
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer
Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer
This study is a Phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus…
- Trial name
- NCT00363415
- Testing
- pemetrexed, etoposide, carboplatin
- Where
- 189 sites in United States, Argentina and 24 more
- Volunteers
- 908 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer (SCLC)
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
The purpose of this study is to assess the safety and efficacy of pembrolizumab plus standard of care (SOC) chemotherapy (etoposide/platinum [EP]) in participants with newly diagnosed extensive stage small cell lung cancer…
- Trial name
- NCT03066778
- Testing
- Pembrolizumab, Normal saline solution, Carboplatin
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 453 people
- Sponsor
- Merck Sharp & Dohme LLC